Peter Tebben, MD
Cards
About
Departments & Organizations
Education & Training
- Fellow
- Mayo Clinic (2006)
- Fellow
- Mayo Clinic (2004)
- Resident
- University of Minnesota (2002)
- MD
- University of Kansas (1998)
- BS
- University of Kansas (1994)
- BS
- Kansas State University (1991)
Research
Publications
2025
Prognostic Factors for Refractory Outcome in Localizing TIO: Experience in a Tertiary Center
Hoong C, Sfeir J, Tebben P, Clarke B. Prognostic Factors for Refractory Outcome in Localizing TIO: Experience in a Tertiary Center. The Journal Of Clinical Endocrinology & Metabolism 2025, dgae911. PMID: 39760693, DOI: 10.1210/clinem/dgae911.Peer-Reviewed Original ResearchRefractory outcomesPredicting cureBaseline biochemistryPredictive of cureChance of cureMarker of cureRenal phosphate wastingSize of tumorYear of diagnosisLevels of FGF23Long-term medical complicationsSurgical tumor marginsUnivariate Cox regressionCulprit tumorsTumor factorsParaneoplastic disordersResection marginsPrognostic factorsFavorable prognosisTertiary centerTumor marginsSurgical removalRetrospective cohortPhosphate wastingFollow-up
2024
Rickets: The Skeletal Disorders of Impaired Calcium or Phosphate Availability
Leopold K, Tebben P. Rickets: The Skeletal Disorders of Impaired Calcium or Phosphate Availability. Chapter 21. Pediatric Endocrinology. 4th Edition. Springer Nature Switzerland AG 2024.Chapters9295 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study
Ing S, Harmatz P, Mora S, Imel E, Tebben P, Warren M, Ma N, Khan A, Palermo A, Decallonne B, Lemoine S, Mantovani G, Linglart A, Wasserman H, Barbosa A, Cardot-Bauters C, Roberts M, Mathew A, Adler S, Zillikens M, Clifton-Bligh R, Rejnmark L. 9295 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study. Journal Of The Endocrine Society 2024, 8: bvae163.383. PMCID: PMC11454366, DOI: 10.1210/jendso/bvae163.383.Peer-Reviewed Original Research8669 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study
Ing S, Harmatz P, Mora S, Imel E, Tebben P, Warren M, Ma N, Khan A, Palermo A, Decallonne B, Lemoine S, Mantovani G, Linglart A, Wasserman H, Barbosa A, Cardot-Bauters C, Roberts M, Mathew A, Adler S, Zillikens M, Clifton-Bligh R, Rejnmark L. 8669 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study. Journal Of The Endocrine Society 2024, 8: bvae163.384. PMCID: PMC11454712, DOI: 10.1210/jendso/bvae163.384.Peer-Reviewed Original ResearchErratum to “An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH).” Kidney International 2023;105:1058–1076
Zhu Z, Bo-Ran Ho B, Chen A, Amrhein J, Apetrei A, Carpenter T, Lazaretti-Castro M, Colazo J, McCrystal Dahir K, Geßner M, Gurevich E, Heier C, Simmons J, Hunley T, Hoppe B, Jacobsen C, Kouri A, Ma N, Majumdar S, Molin A, Nokoff N, Ott S, Peña H, Santos F, Tebben P, Topor L, Deng Y, Bergwitz C. Erratum to “An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH).” Kidney International 2023;105:1058–1076. Kidney International 2024, 106: 159. PMID: 38906648, PMCID: PMC11610493, DOI: 10.1016/j.kint.2024.05.005.Peer-Reviewed Original ResearchCALIBRATE: A phase 3, randomized, open-label study evaluating the efficacy and safety of encaleret (CLTX-305) compared to standard of care in participants with autosomal dominant hypocalcemia type 1 [NCT05680818]
Rejnmark L, Mannstadt M, Brandi M, Ozono K, Tebben P, Mathew A, Roberts M, Adler S, Gafni R. CALIBRATE: A phase 3, randomized, open-label study evaluating the efficacy and safety of encaleret (CLTX-305) compared to standard of care in participants with autosomal dominant hypocalcemia type 1 [NCT05680818]. Endocrine Abstracts 2024 DOI: 10.1530/endoabs.99.oc2.6.Peer-Reviewed Original ResearchCorrection: Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)
Pinto e Vairo F, Kemppainen J, Vitek C, Whalen D, Kolbert K, Sikkink K, Kroc S, Kruisselbrink T, Shupe G, Knudson A, Burke E, Loftus E, Bandel L, Prochnow C, Mulvihill L, Thomas B, Gable D, Graddy C, Garzon G, Ekpoh I, Porquera E, Fervenza F, Hogan M, El Ters M, Warrington K, Davis J, Koster M, Orandi A, Basiaga M, Vella A, Kumar S, Creo A, Lteif A, Pittock S, Tebben P, Abate E, Joshi A, Ristagno E, Patnaik M, Schimmenti L, Dhamija R, Sabrowsky S, Wierenga K, Keddis M, Samadder N, Presutti R, Robinson S, Stephens M, Roberts L, Faubion W, Driscoll S, Wong-Kisiel L, Selcen D, Flanagan E, Ramanan V, Jackson L, Mauermann M, Ortega V, Anderson S, Aoudia S, Klee E, McAllister T, Lazaridis K. Correction: Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD). Journal Of Translational Medicine 2024, 22: 400. PMID: 38689323, PMCID: PMC11061992, DOI: 10.1186/s12967-024-05185-9.Peer-Reviewed Original ResearchAn infant developing hypercalcemia and hypophosphatemia due to the use of exclusively almond milk
Salama M, Tebben P, Al Nofal A. An infant developing hypercalcemia and hypophosphatemia due to the use of exclusively almond milk. Journal Of Pediatric Endocrinology And Metabolism 2024, 37: 375-379. PMID: 38414167, DOI: 10.1515/jpem-2023-0494.Peer-Reviewed Case Reports and Technical NotesConceptsParathyroid hormoneCreatinine ratioUrine calcium-to-creatinine ratioHistory of biliary atresiaCalcium to creatinine ratioMonths prior to presentationAlmond milkCow's milk allergyMilk consumptionMonths of ageSevere hypercalcemiaBiliary atresiaAlternative to cow milkCow's milkD levelsLiver transplantationPlant-based milk alternativesCase reportInitial managementIntravenous fluidsMilk allergyHypercalcemiaMineral contentCalcium concentrationHypophosphatemiaEfficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D
Mohan S, Sheehan M, Tebben P, Wermers R. Efficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D. JCEM Case Reports 2024, 2: luae022. PMID: 38476635, PMCID: PMC10928506, DOI: 10.1210/jcemcr/luae022.Peer-Reviewed Original ResearchLow PTHTherapeutic optionsCalcium levelsNormalization of calcium levelsElevated serum calcium levelsSerum calcium levelsMechanism(s) of actionOral cinacalcetSymptomatic hypocalcemiaCinacalcet doseRecurrent nephrolithiasisUrine calciumRare causeGranulomatous diseaseCinacalcetHypercalcemiaFollow-upSymptomatic benefitGenetic testingBiallelic variantsGenetic mutationsMechanism(s)Mild decreasePTHMalignancyAn update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
Zhu Z, Bo-Ran Ho B, Chen A, Amrhein J, Apetrei A, Carpenter T, Lazaretti-Castro M, Colazo J, McCrystal Dahir K, Geßner M, Gurevich E, Heier C, Simmons J, Hunley T, Hoppe B, Jacobsen C, Kouri A, Ma N, Majumdar S, Molin A, Nokoff N, Ott S, Peña H, Santos F, Tebben P, Topor L, Deng Y, Bergwitz C. An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Kidney International 2024, 105: 1058-1076. PMID: 38364990, PMCID: PMC11106756, DOI: 10.1016/j.kint.2024.01.031.Peer-Reviewed Original ResearchResponse to therapyHereditary hypophosphatemic ricketsPathogenic variantsBone phenotypeSerum phosphateHypophosphatemic ricketsHeterozygous carriersPartial response to therapyPredicting response to therapyRare group of disordersIntact parathyroid hormoneUrine calcium excretionCorrection of hypophosphatemiaSolute carrier familyDecreased serum phosphateBaseline disease severityVariants in vitroOral phosphate supplementationNormalize serum phosphateStandard of careGroup of disordersMutant allelesCarrier familyBiochemical phenotypeKidney phenotype
Academic Achievements & Community Involvement
Clinical Care
Overview
Peter Tebben, MD, is an endocrinologist who specializes in caring for children and adults with a range of hormonal and metabolic bone conditions, including growth disorders, diabetes, and rare bone diseases.
As an associate professor of medicine at Yale School of Medicine and director of the Yale Bone Center, Dr. Tebben supports research on bone metabolism and leads collaborative efforts to improve patient outcomes. “There is considerable need in the rare disease community. It is an exciting space to be a part of because of the development of better treatments that offer hope to people with rare bone disorders,” he says.
Dr. Tebben also highlights the importance of identifying and treating osteoporosis, noting that “because osteoporosis is a silent condition until a fracture occurs, those with high fracture risk often go unrecognized.” Part of his mission is to continue the development of a fracture liaison service to minimize the risk of future fractures. “Much of our effort needs to be focused on identifying patients who have the highest risk of fracture so we can address and minimize that risk with medications and other interventions,” he explains.
Dr. Tebben completed his medical training at the University of Kansas, followed by a combined residency in internal medicine and pediatrics at the University of Minnesota. He then pursued fellowships in adult and pediatric endocrinology at the Mayo Clinic.
Clinical Specialties
Fact Sheets
Low Bone Density
Learn More on Yale MedicineOsteoporosis
Learn More on Yale Medicine
Yale Medicine News
News
News
Get In Touch
Contacts
Yale Medicine
300 Cedar Street
New Haven, CT 06510
United States